In this issue:
Siponimod shows promise in SPMS
Low sun exposure is a risk factor for MS
MS relapse during pregnancy in the new treatment era
Real-world efficacy of fingolimod in RRMS
Influenza vaccination in patients receiving immunotherapies
Response to apheresis differs according to MS pattern
Real-world effectiveness of rituximab and other initial treatment choices
Steroids may reduce the evolution of brain CELs into persistent black holes
Haematological abnormalities with fingolimod and dimethyl fumarate
Outcomes after switching from natalizumab to dimethyl fumarate
Please login below to download this issue (PDF)